Larimar Therapeutics (LRMR) Income from Continuing Operations: 2014-2020
Historic Income from Continuing Operations for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' Income from Continuing Operations rose 72.55% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.50%. This contributed to the annual value of -$45.4 million for FY2019, which is 25.68% up from last year.
- According to the latest figures from Q1 2020, Larimar Therapeutics' Income from Continuing Operations is -$3.6 million, which was up 50.66% from -$7.3 million recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' Income from Continuing Operations registered a high of -$3.6 million during Q1 2020, and its lowest value of -$17.8 million during Q1 2016.
- Over the past 3 years, Larimar Therapeutics' median Income from Continuing Operations value was -$13.1 million (recorded in 2019), while the average stood at -$12.2 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 32.76% in 2016, then soared by 72.55% in 2020.
- Larimar Therapeutics' Income from Continuing Operations (Quarterly) stood at -$10.3 million in 2016, then decreased by 26.76% to -$13.1 million in 2017, then fell by 10.72% to -$14.5 million in 2018, then spiked by 49.65% to -$7.3 million in 2019, then skyrocketed by 72.55% to -$3.6 million in 2020.
- Its last three reported values are -$3.6 million in Q1 2020, -$7.3 million for Q4 2019, and -$12.9 million during Q3 2019.